Endocrine Research Updates

For Medical Professionals

Lorcaserin has been recalled for concerns about elevated cancer risk.
Oral testosterone for adult men with androgen deficiency available, cancer concerns over lorcaserin, and push to bring more biosimilars to market.
The effects of antibiotic use on body weight are evaluated based on use during pregnancy and into the first 4 years of life with findings of a modest, dose-dependent association.
Drug increased brown fat which revs up metabolic effects..
Introducing a beta3-AR agonist, mirabegron, shows increases in energy expenditure, insulin sensitivity, and improved levels of circulating fats, according to ongoing research at the NIH.
Hyperthyroidism appears associated with development of dementia.
Graves’ disease and toxic nodular goiter increase the odds that these patients will develop dementia, including Alzheimer’s disease and vascular dementia, a relationship perhaps driven by prolonged low TSH.
People should get tested for Lp(a) levels at least once to rule out CVD risk.
A strong case is made for testing lipoprotein(a) levels at least once early in life to ascertain future risk of coronary artery disease.
With all the upsides, how often are you actively implementing a management care plan for the many at-risk patients that present in your practice?
One pill delivering 3 forms of glucose lowering power improve outcome.
As the challenge of attaining better glucose control grows, introducing the first three-in-one therapy may lead to better outcomes with greater ease and lower cost.
Insulin clearance has been introduced as a factor in the onset of diabetes
A fresh look at factors affecting progression of type 2 diabetes led Cedars Sinai researchers to consider the possibility that insulin clearance in the liver may play a key role.
When adrenal mass is accidently seen on imaging, assessment may benefit patient.
The presence of adrenal incidentalomas appears increasingly more common and detecting these benign tumors reflects an increased rate of type 2 diabetes but any direct clinical meaning remains elusive, according to recent study findings.
Patients with Graves disease benefit from radioiodine treatment.
Despite conflicting findings, new data refuting any discernible link between increased risk of all cancers gains the endorsement of endocrine community.
Patients who choose radioactive iodine therapy to treat hyperthyroidism and Graves disease are not at increased risk for developing cancer, say experts.
Checking for adequate absorption of levothyroxine is critical in hypothyroidism.
This clinical tool has been used effectively at the Mayo Clinic to identify cases of insufficient LT4 absorption, providing an objective measure to guide patient-physician discussions.
Treating Graves eye disease has been limited to surgery for the severest cases.
Teprotumumab (Tepezza) approved by FDA to make this first and only vision-preserving, pain-reducing treatment available to patients with Graves eye disease.
Doctors should be monitoring patients for risks of chronic kidney disease.
Assessment tool now available to enable clinicians to identify patients with an increased likelihood of developing chronic kidney disease so that preventive measures may be initiated.
People who require insulin will welcome the advent of insulin biosimilars.
Recent regulatory actions clear path for development of insulin biosimilars, expands indications for Pure EPA, and fast paces first possible treatment for end-stage liver disease (NASH).
Diabetes patients who complain of joint pain should be heeded as a sign of gout.
Treating patients at risk for or diagnosed with type 2 diabetes should be closely monitored for gout-related disease.
Stem cell therapy is poised to bypass issues of transplant rejection.
Stem cell transplantation holds ever greater potential for improving glucose control in patients with type 1 diabetes; however, these same patients also face increased morbidity and mortality for cardiovascular disease, an ongoing hurdle.
Advances in stem cell transplantation may replace the need for insulin in type 1 diabetes and may lead to repair of damaged heart tissue following a heart attack.
Will weight loss or good blood sugar control improve type 2 diabetes.
Two leading experts debate the evidence and explore the benefits of initiating a blood glucose-directed or obesity-centric management treatment plan, pointing out the strengths in choosing one disease approach over the other.
A stepwise approach may improve detection of statin intolerance and better cholesterol-lowering management in patients who have had poor medication compliance despite their increased risk of both CVD and type 2 diabetes.
Patients with diabetes must be treated carefully to avoid common complications.
Expert panel addresses barriers to and advancements in achieving optimal hyperkalemia management aiming to improve outcomes regarding kidney disease and cardiovascular events in in patients with diabetes.
Study finds ticagrelor plus aspirin more effective in reducing ischemic cardiovascular events in patients with type 2 diabetes provided there is no heightened concern for excessive bleeding.
close X